

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 8, 2005.

Amy Yost



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Liu et al.

Group Art Unit: Unknown

Serial No.: 10/520,341

Examiner: Unknown

Filed: January 5, 2005

Docket No.: 421/67 PCT/US

Confirmation No.: Unknown

For: PURIFIED AND ISOLATED HEPARAN SULFATE 3-O-SULFOTRANSFERASE ISOFORM 5 NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Serial No.: 10/520,341


Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 02/08/2005

By:



Arles A. Taylor, Jr.
Registration No. 39,395

AAT/acy

Enclosures

Customer No: 25297

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

List of Documents Cited by Applicant



Application No.:	10/520,341
Filing Date:	January 5, 2005
First Named Inventor:	Liu et al.
Group:	Unknown
Examiner:	Unknown
Attorney Docket No.:	421/67 PCT/US

U.S. PATENT DOCUMENTS


Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
	1	International Search Report for corresponding PCT Appl. No. PCT/US03/21094 dated October 7, 2004.	
	2	Xia et al., "Heparan Sulfate 3-O-Sulfotransferase Isoform 5 Generates Both an Antithrombin-binding Site and an Entry Receptor for Herpes Simplex virus, Type 1", <u>Journal of Biological Chemistry</u> , 277 (40): 37912-37919, October 4, 2002.	
	3	Mochizuki et al., "Characterization of a Heparan Sulfate 3-O-Sulfotransferase-5, an Enzyme Synthesizing a Tetrasulfated Disaccharide", <u>Journal of Biological Chemistry</u> , 278 (29): 26780-26787, July 18, 2003.	
	4	Xu et al., "characterization of Heparan Sulphate Sulfotransferase Isoform 6 and Its Role in Assisting the Entry of Herpes Simplex Virus, Type 1", <u>Biochemical Journal</u> : 1-35, August 10, 2004.	



		Yabe et al., "Portable Sulphotransferase Fomain Determines Sequence Specificity of Heparan Sulphate 3-O-Sulfotransferases", <u>Biochemical Journal</u> , 359: 235-241, 2001.	
	6	Kramer et al., "Heparan Sulfate Core Proteins in Cell-Cell Signaling", <u>Annu. Rev. Genet.</u> , 37: 461-484, July 16, 2003.	
	7	Print out of EMBL Sequence Version Archiving for EMBL Accession No. AF503292, printed on September 15, 2004.	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.